Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.
Commentary|Articles|August 5, 2026
- Vol.27/No.9
- Volume 27
- Issue 09
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Road Map
Author(s)Ashling Wahner
Fact checked by: Riley Kandel, Nicole Canfora Lupo
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Advertisement
Advertisement
Antibody-drug conjugates (ADCs) are diversifying the first- and subsequent-line breast cancer treatment arenas, but despite recent FDA approvals providing earlier access to these highly effective treatments, questions remain regarding appropriate decision-making in the second-line setting and beyond.
Related to this article
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Keith Flaherty, MD, FAACR, discusses the 2026 AACR Cancer Progress Report and how the oncology field can build on the report’s findings.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
Advertisement
Advertisement